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Clinical PerspectiveWhat Is New?Traditional Chinese medicine (TCM) was used in nearly every Western hospital in China for the treatment of acute decompensated heart failure, although the extent of use varied substantially by hospital.Although TCM was not used in lieu of evidence‐based therapies for heart failure, we found a signal for harm with the most widely used TCM.What Are the Clinical Implications?Given the frequency of hospitalizations for heart failure in China and the magnitude of use of TCM for this condition, there is an urgent need for further research into the safety and efficacy of TCM, along with standardized approaches for its use in clinical practice.

Introduction {#jah34301-sec-0009}
============

Traditional Chinese medicine (TCM) is commonly used as a complement to evidence‐based therapies for acute illnesses in China.[1](#jah34301-bib-0001){ref-type="ref"} A recent study of acute myocardial infarction found that more than half of patients in Chinese Western medicine hospitals received intravenous TCM as short‐term therapy in 2011.[2](#jah34301-bib-0002){ref-type="ref"} Prior studies suggest that TCM is also frequently used for the management of heart failure (HF), although these studies have been limited to specific provinces or cities in China[3](#jah34301-bib-0003){ref-type="ref"}, [4](#jah34301-bib-0004){ref-type="ref"}, [5](#jah34301-bib-0005){ref-type="ref"} and questions remain about the pervasiveness of TCM in the management of patients hospitalized with HF in China, with implications for clinical practice, research, and policy.

Despite systematic reviews[6](#jah34301-bib-0006){ref-type="ref"}, [7](#jah34301-bib-0007){ref-type="ref"}, [8](#jah34301-bib-0008){ref-type="ref"}, [9](#jah34301-bib-0009){ref-type="ref"} showing inconclusive benefits of TCM in the treatment of HF and a lack of support for TCM in Chinese guidelines,[10](#jah34301-bib-0010){ref-type="ref"}, [11](#jah34301-bib-0011){ref-type="ref"} the limited existing data suggest that TCM is increasingly being used in the management of HF.[12](#jah34301-bib-0012){ref-type="ref"} TCM use may be driven by wide‐scale availability, even in Western medicine hospitals; small studies suggesting benefits in symptoms, hemodynamics, and outcomes[13](#jah34301-bib-0013){ref-type="ref"}, [14](#jah34301-bib-0014){ref-type="ref"}, [15](#jah34301-bib-0015){ref-type="ref"}, [16](#jah34301-bib-0016){ref-type="ref"}, [17](#jah34301-bib-0017){ref-type="ref"}, [18](#jah34301-bib-0018){ref-type="ref"}; and a cultural desire to preserve an ancient medical tradition. Yet, as the Chinese health system strives to become a high‐performing, evidence‐based system, an understanding of the extent of TCM use, the patient factors associated with its use, the extent of hospital‐level variation in use, and whether TCM is used as a substitute for proven therapies for HF would provide the basis for understanding how the quality of HF care might be improved.

Accordingly, we used data from a nationally representative study of patients with acute decompensated HF admitted to Western medicine hospitals throughout China in 2015 to investigate current use patterns of TCM. Collection of TCM data was part of the China PEACE 5r‐HF (China Patient‐Centered Evaluative Assessment of Cardiac Events 5 Retrospective Heart Failure Study).[19](#jah34301-bib-0019){ref-type="ref"} Our aims herein were as follows: (1) to describe practice patterns in the use of TCM during HF hospitalization, including type, combination, and duration; (2) to assess patient characteristics associated with TCM use; (3) to describe hospital variation in use of TCM; and (4) to examine the association of TCM with inpatient bleeding and mortality in an exploratory analysis. Given the frequency of hospitalizations for HF in China, this study can provide important data to guide next steps for determining the efficacy and safety of TCM for acute decompensated HF.

Methods {#jah34301-sec-0010}
=======

The study materials have been made available to other researchers for purposes of replicating the procedure.[19](#jah34301-bib-0019){ref-type="ref"} It is our goal to share the China PEACE 5r‐HF prospective study data; however, at this time, we are unable to do so.

Study Design {#jah34301-sec-0011}
------------

The China PEACE 5r‐HF used a 2‐stage random sampling design to create a nationally representative sample of hospital admissions for HF, with the goal of assessing quality and outcomes of patients hospitalized with HF in 2015. The study design has been described previously.[19](#jah34301-bib-0019){ref-type="ref"} Briefly, we first identified a nationally representative cohort of 189 Western medicine hospitals (a phrase used in China to designate hospitals that are based in Western or conventional therapies, distinguishing them from TCM hospitals). Second, we used systematic random sampling procedures to select 10 004 patients hospitalized for HF in 2015 from the local hospital database of each sampled hospital. As previously described, centralized data abstraction of charts using standardized definitions was assessed for accuracy and quality.[19](#jah34301-bib-0019){ref-type="ref"}

Informed consent was waived for patients not involved in the recruitment or conduct of the study. The Central Ethics Committee at the Chinese National Center for Cardiovascular Diseases and Yale University approved the study. All collaborating hospitals accepted central ethics approval, except for 15 hospitals, which obtained local approval by their internal ethics committees.

Classification of TCM {#jah34301-sec-0012}
---------------------

Herbal medicines, including the name, route of administration, and timing of use in the course of hospitalization, were abstracted from the medical record. Use of nonpharmacological TCM (eg, qigong and acupuncture) is limited in Chinese Western medicine hospitals, if at all used, and therefore was not abstracted. Herbal medicines were classified into groups on the basis of the primary active ingredient. If an herbal medicine included \>1 active ingredient, we classified it according to the primary active ingredient, as previously reported.[2](#jah34301-bib-0002){ref-type="ref"}, [3](#jah34301-bib-0003){ref-type="ref"} We focused on the most commonly used TCMs among patients with HF (defined as being used in \>5% of patients in the sample): Salvia miltiorrhiza, Panax notoginseng, Gingko, Radiax astragali, and Safflower (Table [S1](#jah34301-sup-0001){ref-type="supplementary-material"}). Less frequently used agents were combined into a category of other TCM. The duration of TCM use during hospitalization was based on physicians' orders, counted in days, based on whether any TCM was prescribed on each day of hospitalization.

Statistical Analysis {#jah34301-sec-0013}
--------------------

We describe the frequency of oral and intravenous TCM use among patients admitted for HF, including TCM type, timing of administration (during hospitalization or at discharge), and duration of each TCM use during hospitalization. For the evaluation of medications at discharge, we excluded patients who died or withdrew care during hospitalization. We examined pairwise correlations to assess commonly used combinations of the TCMs during hospitalization; specifically, we calculated the frequency of use of each pair of the 5 TCMs and calculated the Pearson correlation coefficient to examine the association between each TCM pair. In addition, we compared patient‐ and hospital‐level characteristics by the use of any TCM during hospitalization.

To identify factors associated with TCM, we used hierarchical logistic regression models with backward stepwise selection of covariates that were significant at the 0.05 level, using a random effect at the hospital level to account for the patients' clustering within hospitals. We selected explanatory variables, on the basis of clinical judgment and review of the literature, hypothesized to be associated with TCM use, including demographics, clinical characteristics, clinical care management, and hospital‐level characteristics. To assess whether TCM was used in lieu of guideline‐based therapies or recommended diagnostic tests, we tested the association of TCM use with guideline‐based therapies in unadjusted and multivariable models. We transformed continuous variables into categorical variables, according to clinically meaningful cutoff values, and then created dummy variables. For variables with \>1% of data missing, we created a dummy variable indicating missing and included it with the original variable in the adjusted models. Patients with a length of stay of ≤24 hours were excluded. We report odds ratios (ORs) with 95% CIs.

At the hospital level, use of TCM was calculated for each hospital by determining the proportion of patients who received TCM during hospitalization. Hospitals with \<25 total admissions were excluded from this analysis. To estimate the variability in hospital‐level TCM use, we calculated the median OR from the fully adjusted hierarchical model, which represents the average likelihood of a statistically identical patient receiving TCM at one random hospital versus another.[20](#jah34301-bib-0020){ref-type="ref"}

In exploratory analyses, we compared outcomes of in‐hospital bleeding and in‐hospital mortality/withdrawal of care among patients receiving any TCM. Withdrawal from treatment is a common disposition among patients deemed to be actively dying, but who do not want to die in the hospital; this disposition status was adjudicated by clinicians in the coordinating study center. The outcome of in‐hospital mortality or treatment withdrawal is used as a quality measure for hospitals by the Chinese government. We also assessed in‐hospital bleeding given the antiplatelet effects of many of the TCMs and the potential for bleeding, especially if combined with other antiplatelet or anticoagulant use.[21](#jah34301-bib-0021){ref-type="ref"} Bleeding was defined as a documented bleeding event in medical records or a decrease in hemoglobin of ≥3 g/dL. We adjusted variables hypothesized to be associated with in‐hospital bleeding or mortality, including demographics, clinical characteristics, clinical care management (including antiplatelet and anticoagulant agents), and hospital‐level characteristics. In addition, we evaluated in‐hospital outcomes stratified by the duration of Salvia miltiorrhiza therapy on the basis of the distribution of days used into the following: 1, 2 to 9, and \>9 days. We also evaluated in‐hospital outcomes stratified by in‐hospital use of antiplatelet or anticoagulant agents and by Salvia miltiorrhiza.

Statistical analysis was performed with SAS software, version 9.3.

Results {#jah34301-sec-0014}
=======

Use Patterns of TCM {#jah34301-sec-0015}
-------------------

Among 10 004 patients admitted for HF, 74.7% received TCM during hospitalization, which was most often (83.3%) administered intravenously. Only 12.3% were prescribed TCM at discharge. During hospitalization, the most commonly used TCMs were Salvia miltiorrhiza (51.2%), followed by Panax notoginseng (17.1%), Gingko (9.7%), Radiax astragali (7.4%), and Safflower (6.3%). Nearly a quarter (24.2%) of patients received ≥2 types of TCM, with the most common combination being Salvia miltiorrhiza with either Panax notoginseng (8.2%) or Radiax astragali (4.4%) (Table [1](#jah34301-tbl-0001){ref-type="table"}). For patients who received TCM during hospitalization, the median duration for TCM use was 6 days (interquartile range \[IQR\], 1--11 days) and the median length of stay was 9 days (IQR, 6--13 days); 27.1% of patients received only 1‐day therapy of any TCM (Figure [1](#jah34301-fig-0001){ref-type="fig"}). Patients who received 1‐day therapy of Salvia miltiorrhiza accounted for 30.6% of patients who received Salvia miltiorrhiza; similar proportions of patients received 1‐day therapy for Panax notoginseng, Gingko, Radiax astragali, and Safflower (34.8%, 36.5%, 48.3%, and 36.8%, respectively). Most patients received TCM on the first day of admission, and the percentage of TCM use decreased markedly thereafter (Figure [S1](#jah34301-sup-0001){ref-type="supplementary-material"}).

###### 

TCM Use During Hospitalization for HF in Western Medicine Hospitals in China

  Type of TCM                                   Salvia Miltiorrhiza, Ginseng, Ginseng Rubra   Panax Notoginseng   Gingko      Radiax Astragali   Safflower
  --------------------------------------------- --------------------------------------------- ------------------- ----------- ------------------ -----------
  Salvia miltiorrhiza, ginseng, ginseng rubra   5072 (51.2)                                   809 (8.2)           371 (3.7)   433 (4.4)          226 (2.3)
  Panax notoginseng                             ...                                           1696 (17.1)         135 (1.4)   130 (1.3)          56 (0.6)
  Gingko                                        ...                                           ...                 962 (9.7)   81 (0.8)           53 (0.5)
  Radiax astragali                              ...                                           ...                 ...         730 (7.4)          65 (0.7)
  Safflower                                     ...                                           ...                 ...         ...                622 (6.3)

Data are given as number (percentage). HF indicates heart failure; TCM, traditional Chinese medicine.
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![Duration of traditional Chinese medicine (TCM) use during heart failure hospitalization.](JAH3-8-e012776-g001){#jah34301-fig-0001}

Characteristics of Patients and Hospitals Using TCM {#jah34301-sec-0016}
---------------------------------------------------

Patient characteristics were compared between patients who received any TCM and patients who did not receive TCM (Table [2](#jah34301-tbl-0002){ref-type="table"}). The median age of patients was similar (73 \[IQR, 65‐80\] versus 73 \[IQR, 63‐80\] years, respectively). Patients receiving TCM were more likely to be women than those not receiving TCM (49.8% versus 46.3%; *P*=0.003). In addition, bivariate analyses revealed that in‐hospital tests differed between patients receiving TCM and patients who did not (Table [3](#jah34301-tbl-0003){ref-type="table"}). Patients receiving TCM were less likely to have brain natriuretic peptide or NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) testing (53.7% versus 63.9%; *P*\<0.001) or chest x‐ray or computed tomographic scan (74.1% versus 77.0%; *P*=0.004) compared with patients who did not receive TCM.

###### 

Demographic and Clinical Characteristics Stratified by Use of TCM During Hospitalization

  Characteristics                    Overall       TCM           No TCM        *P* Value                 
  ---------------------------------- ------------- ------------- ------------- ----------- ------ ------ ----------
  All                                9909          ...           7400          74.7        2509   25.3   ...
  Demographics                                                                                           
  Age, median (IQR), y               73 (65--80)   73 (65--80)   73 (63--80)   0.0351                    
  Age categories, y                                                                                      
  \<55                               890           9.0           625           8.4         265    10.6   0.0004
  55--64                             1536          15.5          1120          15.2        416    16.6   
  65--74                             2948          29.8          2240          30.3        708    28.2   
  75--84                             3492          35.2          2658          35.9        834    33.2   
  ≥85                                1043          10.5          757           10.2        286    11.4   
  Women                              4845          48.9          3683          49.8        1162   46.3   0.0028
  Medical insurance                  9052          91.4          6773          91.5        2279   90.8   0.2852
  Comorbidities                                                                                          
  Coronary artery disease            6013          60.7          4718          63.8        1295   51.6   \<0.0001
  Hypertension                       5327          53.8          4012          54.2        1315   52.4   0.1171
  Atrial fibrillation                3565          36.0          2704          36.5        861    34.3   0.0449
  Cardiac valvular disease           3334          33.6          2416          32.6        918    36.6   0.0003
  COPD or asthma                     3023          30.5          2158          29.2        865    34.5   \<0.0001
  Dyslipidemia                       5022          50.7          3686          49.8        1336   53.2   0.0029
  Stroke/transient ischemic attack   1992          20.1          1545          20.9        447    17.8   0.0009
  Diabetes mellitus                  1977          20.0          1424          19.2        553    22.0   0.0024
  Chronic renal insufficiency        1621          16.4          1100          14.9        521    20.8   \<0.0001
  Peripheral vascular disease        880           8.9           593           8.0         287    11.4   \<0.0001
  Cancer                             354           3.6           235           3.2         119    4.7    0.0003
  Anemia                             2490          25.1          1804          24.4        686    27.3   0.0031
  Clinical presentation                                                                                  
  Admission to ICU/CCU               549           5.5           352           4.8         197    7.8    \<0.0001
  Cardiogenic shock                  21            0.2           16            0.2         5      0.2    0.8734
  Chest pain                         6409          64.7          4938          66.7        1471   58.6   \<0.0001
  Dyspnea at rest                    5081          51.3          3699          50.0        1382   55.1   \<0.0001
  Orthopnea                          2696          27.2          1956          26.4        740    29.5   0.0029
  Dyspnea on exertion                4962          50.1          3765          50.9        1197   47.7   0.0061
  Paroxysmal nocturnal dyspnea       1526          15.4          1131          15.3        395    15.7   0.5816
  Jugular vein distension            2591          26.2          1911          25.8        680    27.1   0.3754
  S3 present                         16            0.2           9             0.1         7      0.3    \<0.0001
  Pulmonary rales present            5499          55.5          3966          53.6        1533   61.1   \<0.0001
  Hepatojugular reflux positive      536           5.4           420           5.7         116    4.6    \<0.0001
  Lower‐extremity edema              4963          50.1          3728          50.4        1235   49.2   0.6006
  Heart rate, bpm                                                                                        
  \<60                               423           4.3           320           4.3         103    4.1    0.8432
  60--99                             6223          62.8          4652          62.9        1571   62.6   
  ≥100                               3261          32.9          2427          32.8        834    33.2   
  Systolic blood pressure, mm Hg                                                                         
  \<90                               112           1.1           84            1.1         28     1.1    0.9970
  90--139                            5565          56.2          4156          56.2        1409   56.2   
  ≥140                               4221          42.6          3153          42.6        1068   42.6   
  Diastolic blood pressure, mm Hg                                                                        
  \<60                               407           4.1           289           3.9         118    4.7    0.2135
  60--89                             6532          65.9          4893          66.1        1639   65.3   
  ≥90                                2957          29.8          2210          29.9        747    29.8   
  NYHA functional class                                                                                  
  II                                 1087          10.9          797           1.8         290    11.6   \<0.0001
  III                                3980          40.2          3081          41.6        899    35.8   
  IV                                 3060          30.9          2234          30.2        826    32.9   
  Unrecorded                         1782          18.0          1288          17.4        494    19.7   
  GWTG‐HF risk score, median (IQR)   36 (32--41)   36 (32--41)   37 (32--41)   0.0177                    

Bpm indicates beats per minute; CCU, cardiovascular care unit; COPD, chronic obstructive pulmonary disease; GWTG‐HF, Get With The Guidelines--Heart Failure; ICU, intensive care unit; IQR, interquartile range; NYHA, New York Heart Association; TCM, traditional Chinese medicine.
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###### 

Clinical Management Stratified by Use of TCM During Hospitalization

  Variable                                                                                   Overall              TCM                  No TCM              *P* Value                 
  ------------------------------------------------------------------------------------------ -------------------- -------------------- ------------------- ----------- ------ ------ ----------
  All                                                                                        9909                 ...                  7400                74.7        2509   25.3   ...
  Medication during hospitalization[\*](#jah34301-note-0007){ref-type="fn"}                                                                                                          
  ACEI (eligible: 1278)[\*](#jah34301-note-0007){ref-type="fn"}                              627                  49.1                 474                 50.9        153    44.1   0.0301
  ARB (eligible: 1278)[\*](#jah34301-note-0007){ref-type="fn"}                               276                  21.6                 175                 18.8        101    29.1   \<0.0001
  ACEI or ARB (eligible: 1278)[\*](#jah34301-note-0007){ref-type="fn"}                       863                  67.5                 621                 66.7        242    69.7   0.3023
  β‐Blocker (eligible: 1345)[\*](#jah34301-note-0007){ref-type="fn"}                         790                  58.7                 574                 58.8        216    58.5   0.9272
  Aldosterone receptor antagonist (eligible: 1312)[\*](#jah34301-note-0007){ref-type="fn"}   1146                 87.6                 836                 87.6        310    86.6   0.6141
  Anticoagulant (eligible: 1240)[\*](#jah34301-note-0007){ref-type="fn"}                     458                  36.9                 319                 35.6        139    40.5   0.1054
  Tests                                                                                                                                                                              
  BNP/NT‐proBNP                                                                              5578                 56.3                 3974                53.7        1604   63.9   \<0.0001
  Chest x‐ray or CT scan                                                                     7415                 74.8                 5484                74.1        1931   77.0   0.0044
  Echocardiogram                                                                             6436                 65.0                 4765                64.4        1671   66.6   0.0248
  Ejection fraction, %                                                                                                                                                               
  Unknown                                                                                    3634                 36.7                 2761                37.3        873    34.8   0.0238
  \<40                                                                                       1379                 13.9                 1000                13.5        379    15.1   0.0465
  ≥40 and \<50                                                                               1115                 11.2                 821                 11.1        294    11.7   0.3933
  ≥50                                                                                        3781                 38.2                 2818                38.1        963    38.4   0.7887
  Laboratory data median (IQR)                                                                                                                                                       
  Blood urea nitrogen, mmol/L                                                                7 (5--10)            7 (5--9)             7 (5--10)           \<0.0001                  
  Serum creatinine, μmol/L                                                                   0.95 (0.76--1.25)    0.95 (0.76--1.23)    0.98 (0.77--1.34)   \<0.0001                  
  Serum sodium, mEq/L                                                                        139.6 (136.5--142)   139.7 (136.7--142)   139.2 (136--142)    0.0507                    
  Total cholesterol, mmol/L                                                                  4.0 (3.3--4.8)       4.0 (3.3--4.8)       4.0 (3.3--4.8)      0.0514                    
  Glucose, mmol/L                                                                            6 (5.0--7.6)         5.9 (5--7.5)         6.1 (5.1--7.8)      0.0006                    
  Hemoglobin, g/L                                                                            129 (113--143)       129 (114--143)       128 (112--144)      0.2436                    
  Serum potassium, mmol/L                                                                    4 (3.6--4.4)         4 (3.6--4.4)         4 (3.6--4.4)        0.6995                    
  Medication at discharge[\*](#jah34301-note-0007){ref-type="fn"}                                                                                                                    
  ACEI[\*](#jah34301-note-0007){ref-type="fn"} (eligible: 1261)                              442                  35.0                 326                 35.4        116    34.1   0.6728
  ARB[\*](#jah34301-note-0007){ref-type="fn"} (eligible: 1261)                               209                  16.6                 129                 14.0        80     23.5   \<0.0001
  ACEI or ARB[\*](#jah34301-note-0007){ref-type="fn"} (eligible: 1261)                       648                  51.4                 454                 49.3        194    57.1   0.0144
  β‐Blocker[\*](#jah34301-note-0007){ref-type="fn"} (eligible: 1321)                         609                  46.1                 438                 45.6        171    47.5   0.5325
  Aldosterone receptor antagonist[\*](#jah34301-note-0007){ref-type="fn"} (eligible: 1289)   836                  64.9                 598                 63.7        238    68.0   0.1489
  Anticoagulant[\*](#jah34301-note-0007){ref-type="fn"} (eligible: 1218)                     54                   4.4                  25                  2.8         29     8.6    \<0.0001

ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CT, computed tomographic; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; TCM, traditional Chinese medicine.

Analysis among eligible patients with indications and without contraindications.
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Although nearly all the sampled hospitals (99.4%) used TCM in at least some patients with HF, there was significant variation in frequency of use across hospitals (Figure [2](#jah34301-fig-0002){ref-type="fig"}). The median frequency of hospital TCM use was 81.6% (range, 0%--100%; IQR, 67.2%--91.6%). We also observed variation in TCM use by hospital subtype (Figure [3](#jah34301-fig-0003){ref-type="fig"}). The median rate of TCM use was 86.7% (IQR, 76.6%--93.3%) in nonteaching hospitals compared with 78.6% (IQR, 59.3%--88.2%) in teaching hospitals; and it 84.2% (IQR, 69.8%--92.2%) in non--coronary artery bypass grafting hospitals compared with 74.8% (IQR, 46.9%--82.1%) in coronary artery bypass grafting hospitals.

![Variation of inpatient traditional Chinese medicine (TCM) use among participating hospitals.](JAH3-8-e012776-g002){#jah34301-fig-0002}

![Traditional Chinese medicine use by hospital subtype. CABG indicates coronary artery bypass grafting.](JAH3-8-e012776-g003){#jah34301-fig-0003}

Patient and Hospital Characteristics Associated With TCM Administration {#jah34301-sec-0017}
-----------------------------------------------------------------------

In hierarchical logistic regression models, some patient factors were strongly associated with TCM (Figure [4](#jah34301-fig-0004){ref-type="fig"}). Patients with coronary artery disease were more likely to receive TCM (OR, 1.73; 95% CI, 1.53--1.95), as were those with hypertension (OR, 1.21; 95% CI, 1.08--1.35) or stroke (OR, 1.32; 95% CI, 1.15--1.51). However, patients with chronic obstructive pulmonary disease (OR, 0.79; 95% CI, 0.70--0.89), diabetes mellitus (OR, 0.86; 95% CI, 0.75--0.98), chronic kidney disease (OR, 0.74; 95% CI, 0.64--0.85), and cancer (OR, 0.74; 95% CI, 0.57--0.95) were less likely to receive TCM. Patients presenting with chest pain were more likely to receive TCM (OR, 1.19; 95% CI, 1.06--1.34), whereas patients presenting with dyspnea at rest (OR, 0.87; 95% CI, 0.78--0.96) or pulmonary rales (OR, 0.72; 95% CI, 0.64--0.80) were less likely to receive TCM. Patients who received β blockers during hospitalization were more likely to receive TCM (OR, 1.38; 95% CI, 1.23--1.55); other evidenced‐based therapies were not significantly associated with TCM use.

![Patient‐ and hospital‐level characteristics associated with traditional Chinese medicine (TCM). CABG indicates coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; OR, odds ratio.](JAH3-8-e012776-g004){#jah34301-fig-0004}

We observed substantial variation in the use of TCM across hospitals (median OR, 3.29; 95% CI, 2.82--3.76), suggesting that the average odds of a patient receiving TCM at one random hospital versus another varied 3‐fold after adjusting for patient and treatment characteristics. Approximately 32% of the variance in use of TCM among patients was explained by the nested effect (or clustering) of patients among hospitals (intraclass correlation, 0.32). Patients treated in teaching hospitals (OR, 0.49; 95% CI, 0.32--0.75) or hospitals with capability of coronary artery bypass grafting (OR, 0.45; 95% CI, 0.28--0.73) were less likely to receive TCM.

Association of TCM With Inpatient Outcomes {#jah34301-sec-0018}
------------------------------------------

In fully adjusted hierarchical models, there was no association with TCM use and inpatient bleeding or with combination of mortality or treatment withdrawal (Table [4](#jah34301-tbl-0004){ref-type="table"}). We observed a significant increase in the risk for bleeding (OR, 1.39; 95% CI, 1.03--1.88) and death (OR, 1.36; 95% CI, 1.04--1.79) during hospitalization with Salvia miltiorrhiza (Table [S2](#jah34301-sup-0001){ref-type="supplementary-material"}, Figure [S2](#jah34301-sup-0001){ref-type="supplementary-material"}). The risk of bleeding was significantly higher in patients who received at least 2 days of Salvia miltiorrhiza therapy (Table [S3](#jah34301-sup-0001){ref-type="supplementary-material"}). The risk of death was significantly higher in patients receiving Salvia miltiorrhiza for up to 9 days; however, mortality was not significantly higher in patients who received \>9 days of Salvia miltiorrhiza therapy. In addition, the use of antiplatelets or anticoagulants with and without Salvia miltiorrhiza was not associated with greater in‐hospital bleeding or death (Table [S4](#jah34301-sup-0001){ref-type="supplementary-material"}).

###### 

Hospital Events Stratified by Use of TCM During Hospitalization

  Variable                                        Overall   TCM   No TCM   *P* Value   Adjusted OR for any TCM   95% CI                   
  ----------------------------------------------- --------- ----- -------- ----------- ------------------------- -------- -------- ------ --------------
  All                                             9909      ...   ...      ...         ...                       ...      ...      ...    ...
  In‐hospital bleeding                            255       2.6   167      2.3         88                        3.5      0.0006   1.11   (0.86--1.45)
  In‐hospital mortality or treatment withdrawal   342       3.4   242      3.3         100                       4.0      0.0898   1.08   (0.84--1.39)

OR indicates odds ratio; TCM, traditional Chinese medicine.
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Discussion {#jah34301-sec-0019}
==========

In this nationally representative study of patients with HF admitted to Western medicine hospitals in China, three fourths of patients received TCM during HF hospitalization, and TCM was used in nearly all of the hospitals. One third of the agents used were prescribed for only 1 day during hospitalization, and only 12% of patients were prescribed TCM on discharge, in contrast with the longer durations of therapy studied in clinical trials. We did not find evidence that TCM was being used in lieu of evidence‐based therapies; instead, our findings suggest that TCM is used as a complementary therapy in the management of HF. Variation in use of TCM could be explained, in part, by patient‐ and hospital‐level factors, with ≈32% of the variation driven by hospital characteristics. Specifically, patients with statistically identical demographics and clinical findings on presentation and who received similar evidence‐based treatments for HF, on average, were ≈3 times more likely to receive TCM at some hospitals versus others. Finally, we observed a signal for increased bleeding and mortality with Salvia miltiorrhiza; although bleeding with this TCM has previously been described,[22](#jah34301-bib-0022){ref-type="ref"} the increase in mortality was an unexpected finding, warranting further investigation.

Our findings extend prior literature by demonstrating the frequent use of TCM among patients hospitalized with HF in a nationally representative and large sample. A previous national study observed TCM was used in the short‐term treatment of acute myocardial infarction in nearly all Western medicine hospitals throughout China, and most patients hospitalized with acute myocardial infarction received TCM.[2](#jah34301-bib-0002){ref-type="ref"} Our study demonstrates that TCM use was also prevalent in the clinical management of patients hospitalized with HF. Several reasons may account for its prevalence. First, treatment with TCM for HF is an ancient tradition in China that can be traced back to \>1000 years. For many diseases, TCM combined with Western medicine is well accepted by physicians and patients.[23](#jah34301-bib-0023){ref-type="ref"} Second, TCM is a fully institutionalized part of health care in China.[24](#jah34301-bib-0024){ref-type="ref"} Specifically, the Chinese government encourages the use of TCM, as well as research about the efficacy and safety of TCM. Most of the TCMs, including both oral and intravenous types, are covered by the basic insurance provided by the government.[25](#jah34301-bib-0025){ref-type="ref"} To ensure the quality of TCM, the China Food and Drug Administration has strengthened the monitoring of manufacturing and postmarket safety of TCM in recent years. As of 2016, TCM was prescribed to \>70 million outpatients and \>2.5 million inpatients, accounting for 14% to 20% of healthcare visits in China.[26](#jah34301-bib-0026){ref-type="ref"} Third, some studies show that TCM may improve cardiac function and symptoms of HF. A systematic review[8](#jah34301-bib-0008){ref-type="ref"} of 9 randomized controlled trials assessing TCMs containing Salvia miltiorrhiza/danshen, Panax notoginseng, and Gingko, the most commonly used TCMs in this study, revealed evidence to support improvement in ventricular remodeling and function. Still, more studies designed and powered to find differences in patient outcomes, including data on long‐term outcomes, are needed.

Given the increasing number of publications showing therapeutic effects of TCM for HF, we were interested in assessing whether TCM was prescribed according to the duration tested in the most recent clinical trials, which might indicate that prescribing physicians are early adopters of emerging evidence for TCM. However, we found that TCM was used for much shorter durations than tested in prior trials. Specifically, in the most recent well‐conducted randomized clinical trials (Table [S5](#jah34301-sup-0001){ref-type="supplementary-material"}) assessing the effect of TCM for HF, a consistent duration of at least 4 weeks was tested. Yet, in our sample of contemporary HF admissions, the median duration of TCM treatment was only 6 days, despite the median length of stay being 9 days. In addition, among patients who received TCM, only two thirds were prescribed them for \>1 day. These findings suggest that the use of TCM may be driven more by cultural and clinical norms for treating symptoms and disease, than by the existing published data supporting their efficacy. Further investigations exploring the underlying reasons guiding the decision to use TCM in patients with HF, as well as their duration of use, are needed.

Patients with comorbid coronary artery disease and those who presented with chest pain were more likely to be prescribed TCM. Previous studies have demonstrated benefits of TCM for treating ischemic disease, including improved angiographic coronary blood flow and reflow,[27](#jah34301-bib-0027){ref-type="ref"} decreased stent restenosis, and less angina.[28](#jah34301-bib-0028){ref-type="ref"} Similarly, many studies showed a beneficial effect of TCM in the treatment of hypertension[29](#jah34301-bib-0029){ref-type="ref"}, [30](#jah34301-bib-0030){ref-type="ref"} and stroke,[31](#jah34301-bib-0031){ref-type="ref"}, [32](#jah34301-bib-0032){ref-type="ref"} which may explain the more frequent use of TCM among patients with comorbid hypertension and stroke.

We examined TCM use at the hospital level, the first such report, to our knowledge. Our findings revealed significant heterogeneity in the proportion of patients receiving TCM during hospitalization across hospitals. In some hospitals, none of the patients received TCM, whereas in others, all of the patients hospitalized with HF received TCM. Nonteaching hospitals were more likely to use TCM than teaching hospitals. Similarly, hospitals located in the central and western regions, which are generally poorer and tend to be less westernized, were more likely to use TCM.

Several limitations should be considered in the interpretation of these findings. First, as HF often occurs in the context of other medical illnesses, it is unknown whether the TCMs used in this study were intended to treat HF, versus other comorbidities, such as coronary artery disease, hypertension, or stroke. However, none of the Chinese guidelines for these conditions recommends TCM as a standard therapy. Second, our approach to examining factors associated with TCM was based on data from a retrospective review of medical records, which may not capture the full spectrum of patient, physician, or hospital characteristics that might influence use of TCM. Third, we are not able to evaluate the effects of other active TCM ingredients that are not the primary ingredient. In abstracting TCMs from the medical charts, we classified TCMs according to the primary active ingredient only; we did not document the name brand, which would be needed to identify other active ingredients. Although it is plausible that these nonprimary active ingredients may have had some effect, this classification is consistent with other studies of TCMs.[2](#jah34301-bib-0002){ref-type="ref"}, [3](#jah34301-bib-0003){ref-type="ref"} Finally, our work examining associations of TCM with in‐hospital outcomes is exploratory. Doses and formulations of TCM were not standardized, and we may not have had adequate power to exclude a clinically important association. In addition, we cannot confirm that in‐hospital bleeding occurred after TCM use for all patients.

In conclusion, TCM was widely used among patients admitted for HF in Western medicine hospitals throughout China. Although nearly all hospitals in our sample used TCM, we observed that some hospitals were \>3 times as likely to use TCM for patients admitted with HF than other hospitals. Given the overall high use of TCM, along with the signal for potential harm with the most commonly used TCM, there is an urgent need for the study of the safety and efficacy of TCM, along with standardized approaches for its use in clinical practice.
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